Literature DB >> 7775175

A preliminary report on hyperbaric oxygen in the relief of migraine headache.

D E Myers1, R A Myers.   

Abstract

Oxygen inhalation was early advocated as a treatment for migraine headache. It has been theorized that the efficacy of raising blood oxygen levels in vascular headache is mediated by vasoconstriction and metabolic effects. Hyperbaric oxygen can provide a much greater level of blood oxygenation than can provide a much greater level of blood oxygenation than normobaric oxygen, and in recent studies it has been used in the treatment of cluster headache. The purpose of this study was to compare the effects of hyperbaric oxygen and normobaric oxygen in migraine. Twenty migraineurs were divided randomly into two groups and studied in a hyperbaric chamber during a typical headache attack. Global headache severity was measured by a verbal descriptor scale before and after exposure to oxygen. One group received 100% oxygen at 1 atmosphere of pressure (normobaric) while the other received 100% oxygen at 2 atmospheres of pressure (hyperbaric). One of the 10 patients in the normobaric group achieved significant relief of headache symptoms, while 9 of 10 in the hyperbaric group found relief. Based on a chi-square test, this difference is significant at the P < .005 level. Those patients who did not find significant relief from normobaric oxygen were given hyperbaric oxygen as above. All nine found significant relief. The results suggest that hyperbaric (but not normobaric) oxygen may be useful in the abortive management of migraine headache. Possibilities for the mechanism of this effect, in addition to vasoconstriction, include an increase in the rate of energy-producing and neurotransmitter-related metabolic reactions in the brain which require molecular oxygen.

Entities:  

Mesh:

Year:  1995        PMID: 7775175     DOI: 10.1111/j.1526-4610.1995.hed3504197.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  9 in total

Review 1.  Nonpharmacologic treatment of migraine.

Authors:  Peter S Sándor; Judit Afra
Journal:  Curr Pain Headache Rep       Date:  2005-06

2.  Hyperbaric oxygen treatment induces a 2-phase antinociceptive response of unusually long duration in mice.

Authors:  Eunhee Chung; Lisa M Zelinski; Yusuke Ohgami; Donald Y Shirachi; Raymond M Quock
Journal:  J Pain       Date:  2010-04-24       Impact factor: 5.820

Review 3.  Endogenous mechanisms underlying the activation and sensitization of meningeal nociceptors: the role of immuno-vascular interactions and cortical spreading depression.

Authors:  Dan Levy
Journal:  Curr Pain Headache Rep       Date:  2012-06

4.  Role of spinal GABA receptors in the acute antinociceptive response of mice to hyperbaric oxygen.

Authors:  Abigail L Brewer; Shulin Liu; Amber V Buhler; Donald Y Shirachi; Raymond M Quock
Journal:  Brain Res       Date:  2018-08-03       Impact factor: 3.252

Review 5.  [Hyper- or normobaric oxygen therapy to treat migraine and cluster headache pain. Cochrane review].

Authors:  A Schnabel; M Bennet; F Schuster; N Roewer; P Kranke
Journal:  Schmerz       Date:  2008-04       Impact factor: 1.107

6.  The impact of anesthetics and hyperoxia on cortical spreading depression.

Authors:  Chiho Kudo; Ala Nozari; Michael A Moskowitz; Cenk Ayata
Journal:  Exp Neurol       Date:  2008-04-11       Impact factor: 5.330

7.  A prolonged nitric oxide-dependent, opioid-mediated antinociceptive effect of hyperbaric oxygen in mice.

Authors:  Lisa M Zelinski; Yusuke Ohgami; Eunhee Chung; Donald Y Shirachi; Raymond M Quock
Journal:  J Pain       Date:  2008-10-31       Impact factor: 5.820

Review 8.  Hyperbaric oxygen therapy in chronic pain management.

Authors:  Senol Yildiz; Gunalp Uzun; M Zeki Kiralp
Journal:  Curr Pain Headache Rep       Date:  2006-04

Review 9.  Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache.

Authors:  Michael H Bennett; Christopher French; Alexander Schnabel; Jason Wasiak; Peter Kranke; Stephanie Weibel
Journal:  Cochrane Database Syst Rev       Date:  2015-12-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.